文献速递间质性肺疾病

Zinpentraxin Alfa治疗特发性肺纤维化的随机III期STARSCAPE试验

Zinpentraxin Alfa for Idiopathic Pulmonary Fibrosis: The Randomized Phase III STARSCAPE Trial.
PubMed 文献 · Am J Respir Crit Care Med · 2024-01-01

这项52周、双盲、安慰剂对照的III期试验在29国275个中心纳入664例IPF患者,随机接受静脉安慰剂或zinpentraxin alfa 10 mg/kg每4周一次。预设无效性分析显示无治疗获益后试验提前终止,第52周FVC绝对变化两组相似(-214.89 ml vs -235.72 ml,P=0.5420),次要终点亦无明显疗效。

要点

  • zinpentraxin alfa 10 mg/kg每4周一次未改善IPF患者第52周FVC变化。
  • 预设无效性分析显示无治疗获益,试验提前终止。
  • 两组不良事件发生率分别为72.3%和74.6%,安全性无新信号。

核心结论

  • zinpentraxin alfa治疗对IPF患者未优于安慰剂。

研究设计与样本

  • 52周、双盲、安慰剂对照、 pivotal III期试验,在29个国家275个中心开展。
  • 664例IPF患者按1:1随机接受静脉安慰剂或zinpentraxin alfa 10 mg/kg每4周一次。
  • 主要终点为基线至第52周FVC绝对变化,次要终点包括FVC占预计值百分比和6分钟步行距离的绝对变化。

主要发现

  • 664例随机患者中333例分配至安慰剂组、331例至zinpentraxin alfa组,4例从未接受研究药物。
  • 预设无效性分析显示无治疗获益后试验提前终止。
  • 最终分析中,基线至第52周FVC绝对变化在安慰剂组为-214.89 ml、zinpentraxin alfa组为-235.72 ml(P=0.5420)。
  • 次要终点未见明显治疗效应。
  • 安慰剂组和zinpentraxin alfa组分别有72.3%和74.6%的患者经历至少一次不良事件。

关键数值与推荐

  • 主要终点第52周FVC绝对变化:安慰剂组-214.89 ml vs zinpentraxin alfa组-235.72 ml,P=0.5420。
  • 不良事件发生率:安慰剂组72.3%,zinpentraxin alfa组74.6%。

临床怎么用

  • 不推荐对IPF患者使用zinpentraxin alfa,因III期试验未显示优于安慰剂。
  • 该试验的无效性分析提前终止经验可用于优化IPF未来试验设计。

局限性

  • 试验因预设无效性分析提前终止,可能影响次要终点和安全性数据的完整解释。
  • 事后分析提示II期临床获益可能由两例安慰剂组患者FVC极端下降所致。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Rationale: A phase II trial reported clinical benefit over 28 weeks in patients with idiopathic pulmonary fibrosis (IPF) who received zinpentraxin alfa. Objectives: To investigate the efficacy and safety of zinpentraxin alfa in patients with IPF in a phase III trial. Methods: This 52-week phase III, double-blind, placebo-controlled, pivotal trial was conducted at 275 sites in 29 countries. Patients with IPF were randomized 1:1 to intravenous placebo or zinpentraxin alfa 10 mg/kg every 4 weeks. The primary endpoint was absolute change from baseline to Week 52 in FVC. Secondary endpoints included absolute change from baseline to Week 52 in percent predicted FVC and 6-minute walk distance. Safety was monitored via adverse events. Post hoc analysis of the phase II and phase III data explored changes in FVC and their impact on the efficacy results. Measurements and Main Results: Of 664 randomized patients, 333 were assigned to placebo and 331 to zinpentraxin alfa. Four of the 664 randomized patients were never administered study drug. The trial was terminated early after a prespecified futility analysis that demonstrated no treatment benefit of zinpentraxin alfa over placebo. In the final analysis, absolute change from baseline to Week 52 in FVC was similar between placebo and zinpentraxin alfa (-214.89 ml and -235.72 ml; P = 0.5420); there were no apparent treatment effects on secondary endpoints. Overall, 72.3% and 74.6% of patients receiving placebo and zinpentraxin alfa, respectively, experienced one or more adverse events. Post hoc analysis revealed that extreme FVC decline in two placebo-treated patients resulted in the clinical benefit of zinpentraxin alfa reported by phase II. Conclusions: Zinpentraxin alfa treatment did not benefit patients with IPF over placebo. Learnings from this program may help improve decision making around trials in IPF. Clinical trial registered with www.clinicaltrials.gov (NCT04552899).

来源:Am J Respir Crit Care Med,查看原文。版权归原作者所有。

引用

  1. Richeldi L, Schiffman C, Behr J, et al. Zinpentraxin Alfa for Idiopathic Pulmonary Fibrosis: The Randomized Phase III STARSCAPE Trial. Am J Respir Crit Care Med. 2024. PMID: 38354066. doi:10.1164/rccm.202401-0116OC

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。